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such as improved medication adherence. The objective of this
study was to estimate the impact of type of pharmacy
(chain/independent) on adherence to Oral Hypoglycemic Agents
(OHAs) in patients newly diagnosed with type 2 diabetes.
METHODS: Newly diagnosed type 2 diabetes patients during a
four-year period were identiﬁed from a Medicaid claims data-
base. The provider of the index prescription was classiﬁed as a
chain or independent pharmacy. Utilization patterns (switching,
augmentation, discontinuation, non-modiﬁcation) and adher-
ence to OHAs (Medication Possession Ratios) were computed
for a 12-month follow-up period from the date of the index
OHA prescription. A multivariate framework was used to esti-
mate the impact of type of pharmacy on utilization patterns and
adherence, controlling for demographics, co-morbidity, diabetes
severity, and regimen complexity. RESULTS: A total of 1214
newly diagnosed type-2 diabetes patients were identiﬁed (inde-
pendent pharmacy = 430; chain pharmacy = 784). Utilization
patterns were not signiﬁcantly different between patients ﬁlling
their prescriptions at an independent pharmacy versus those
ﬁlling prescriptions at a chain pharmacy. Independent-sample t-
tests indicated that adherence to OHAs (Mean ± S.D) was sig-
niﬁcantly higher for patients ﬁlling their prescriptions at a
independent pharmacy (0.90 ± 0.11) as compared to those ﬁlling
prescriptions at a chain pharmacy (0.87 ± 0.13) [p = 0.02].
Results of a semi-log OLS model indicated that controlling for
covariates, patients ﬁlling prescriptions at an independent phar-
macy had 2.30% higher adherence to OHAs as compared to
those ﬁlling prescriptions at a chain pharmacy [p = 0.04]. CON-
CLUSION: Patients ﬁlling prescriptions at independent pharma-
cies have signiﬁcantly higher adherence to OHAs as compared
to those ﬁlling prescriptions at chain pharmacies. This improved
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications.
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OBJECTIVES: Long-term adherence to medications among type
2 diabetes patients may have an impact on health care costs and
hospitalizations. This study examined differences in medication
adherence, and persistence, hospitalization and health care costs
between patients with type 2 diabetes enrolled in the North Car-
olina Medicaid newly starting thiazolidinedione (TZD) therapy
and those starting other oral antidiabetic agents. METHODS: A
total of 1774 patients newly starting TZD therapy between July
2001 and June 2002 were compared to 218 patients starting met-
formin and 1199 patients starting sulfonylureas for health care
costs and outcomes in the post-medication start year. The
cohorts were followed for 30 months (July 2002 to December
2004) to examine if there were any differences in outcomes such
as adherence, persistence, hospitalization and total health care
costs that could be associated with type of therapy. Multivariate
regression techniques incorporating health care utilization in the
year prior to start of new therapy were utilized to determine 
the net cost impact of one therapy versus the other. RESULTS:
The average health care costs were less for patients on TZD
[836.34 (1176.30)] as compared to other two groups. Persistence
and adherence rate to TZDs was similar to other Sulfonylureas,
and higher than Metformin. Multivariate analysis showed that
patients on TZD therapy had signiﬁcantly higher medication
adherence while metformin users had signiﬁcantly lower med-
ication adherence as compared to sulfonylureas. Patients on
TZD therapy were associated with decreased likelihood of hos-
pitalization and decreased number of hospitalizations as com-
pared to sulfonylureas users. Adherence to new therapy was
signiﬁcantly associated with decreased number of hospitaliza-
tions. CONCLUSIONS: Long-term use of thiazolidinedione
therapy in a Medicaid-enrolled type 2 diabetic population was
associated with signiﬁcantly greater treatment adherence, and
reduced hospitalization in the post-start year compared to
patients starting other oral antidiabetic agents.
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OBJECTIVE: Medication adherence is an important factor in
improving outcomes among type 2 diabetes patients. The
primary objective of this study was to determine the association
between race and medication adherence among type 2 diabetes
patients. The secondary objectives were to determine the associ-
ation between type of therapy and medication adherence and to
determine if race has an inﬂuence in determining the medication
adherence to speciﬁc antidiabetic therapy. METHODS: This ret-
rospective cohort study was conducted using North Carolina
Medicaid prescription claims. A total of 1774 patients newly
starting Thiazolidinediones were compared to 216 patients start-
ing metformin and 1179 patients starting Sulfonylureas. Med-
ication adherence was measured as Medication Possession Ratio
using prescription reﬁll patterns. Multivariate regression analy-
ses were used to determine the difference in adherence rates
adjusting for other covariates. RESULTS: Whites’ had highest
mean medication adherence rate of 59% which was signiﬁcantly
different from Blacks (54%) (p < 0.05). Thiazolidinediones’
adherence rate of 60% was signiﬁcantly higher than metformin
(22%) and sulfonylurea group (57%) (both p < 0.05). Whites
had higher adherence to all the therapies as compared to other
two races. In multivariate analyses, the adherence rate of black
patients was found to be signiﬁcantly lower by 12% as compared
to whites after adjusting for other variables (p < 0.05). Met-
formin users were associated with 62% decrease in adherence
rate as compared with the sulfonylurea group and 63% decrease
in adherence rate as compared with thiazolidinediones (both p <
0.05). CONCLUSION: Antidiabetic medication adherence was
associated with race as well as type of therapy. Future research
should focus on investigating patient-related and therapy-related
factors affecting medication adherence in type 2 diabetes
patients.
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OBJECTIVE: The purpose of this study was to determine the
extent of adherence among diabetic patients to treatments and
A41Abstracts
medications, to assess its impact on healthcare costs, and to
deduce areas for further research. METHODS: A systematic lit-
erature search (1990–2004) using an exhaustive list of relevant
search terms was performed to identify articles with qualitative
and quantitative data on adherence with oral anti-diabetic agents
(OAs) and insulin. Studies describing the economic impact of
non-adherence, including impact of medication co-payment on
level of adherence, were also reviewed. Electronic Medline® and
PubMed® searches along with manual review of bibliographies
were conducted in different phases for article retrieval.
RESULTS: Adequate documentation of adherence and its eco-
nomic impact was found in 51 studies. Most adherence studies
were conducted on OAs. Thirty-seven retrospective studies
showed that adherence to diabetes treatment ranged from 31%
to 90%, mostly measured by medication possession ratio, with
levels slightly lower among insulin patients. Results varied due
to a diversity of applied methodologies, where deﬁnitions of
compliance and persistence were calculated differently. Race,
multiple dosing, mode of administration, and patients’ behav-
ioral factors were signiﬁcantly associated with adherence levels.
Economic consequences of poor adherence were identiﬁed from
seven studies (ﬁve retrospective, one patient survey, and one lon-
gitudinal cohort study), which demonstrated an increase in hos-
pitalizations, premature disability, and other adverse events
resulting in higher healthcare costs. Increasing co-payments (7
retrospective studies) resulted in a decrease in taking medications
leading to increased adverse events and subsequent healthcare
costs. CONCLUSIONS: This review conﬁrms the lack of ade-
quate treatment adherence among patients with diabetes and
illustrates the considerable economic impact. More sophisticated
methods of determining medication adherence have the poten-
tial to more accurately estimate adherence rates. Research
demonstrating adherence to insulin therapies, particularly insulin
pens, and related economic consequences are lacking in the 
literature.
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OBJECTIVE: The objective of this study was to investigate the
association between pain response and health-related quality of
life (HRQoL) in patients with diabetic peripheral neuropathic
pain (DPNP). METHODS: EQ-5D data was collected at base-
line and endpoint in three large placebo controlled randomised
trials which evaluated duloxetine treatment for DPNP over a 12-
week horizon. Patients had a clinical diagnosis of pain due to
bilateral peripheral neuropathy caused by diabetes, had a mean
24-hour average pain severity score ≥ 4 on the 11 point Likert
scale (“0 = no pain” and “10 = pain as bad as you can imagine”)
and suffered from daily pain for at least 6 months. Treatment
response was based on the level of change observed in the
average pain severity score. Three levels of clinically meaningful
pain response were deﬁned: full response (≥50% change in
average pain severity), partial response (30 to 49% change
average pain severity), and no response (<30% change in average
pain severity). Utility data at the trial endpoint were pooled and
stratiﬁed into the corresponding pain response thresholds.
RESULTS: Patients had pain and utility scores measured at base-
line (n = 1139) and trial endpoints (n = 998) across the three
randomised trials. The average pain score at baseline was 5.8 ±
1.5 with a corresponding utility score of 0.58 ± 0.26. At trial
endpoint, patients in the no response to treatment category had
lower utility scores (0.61 ± 0.24) compared to patients with
either a partial response (0.70 ± 0.16) or full response (0.78 ±
0.16). In addition, a statistically signiﬁcant negative correlation
was found, indicating that increasing pain severity was strongly
associated with lower HRQoL in DPNP patients. CONCLU-
SION: Pain response had a considerable impact on HRQoL in
DPNP patients. In addition, pain severity scores were signiﬁ-
cantly associated with lower HRQoL.
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OBJECTIVE: This study aimed to estimate the health-related
quality of life (HRQL) utility score for patients with diabetes
mellitus Type 1 and Type 2 on insulin and/or oral treatment using
EQ-5D and to compare differences in HRQL for controlled and
uncontrolled patients. METHODS: We surveyed 157 patients in
a cross sectional study with treated Type 1 and Type 2 diabetes
in Sweden (age range 20–65 years). Physicians recorded demo-
graphic and treatment information, including medications for
diabetes. HRQL was measured using the EQ-5D questionnaire
and was ﬁlled in by the patients at a physician visit. We evalu-
ated the differences between groups (e.g. treatment regimes)
using GLM-models. All statistical tests were performed at the
0.05-level of signiﬁcance and were all two-sided. EQ-5D was
linked to utility weights using an algorithm that converges
ordinal ratings into a weighed composite score. RESULTS: The
mean utility score for the entire sample was 0.81 (SD 0.21) with
a median of 0.79 (min -0.18, max 1.00). Patients with Type 1
diabetes had a higher mean utility score (0.88) than patients with
Type 2 diabetes. Patients treated with a mixed regimen of oral
antidiabetics and insulin reported a lower utility score (0.76).
However, differences between treatment groups were not signif-
icant at the 5% level (p = 0.063). No signiﬁcant difference was
estimated in the health utility score for patients with controlled
diabetes according to Swedish guidelines in comparison to
uncontrolled patients. Women had signiﬁcantly lower EQ-5D
utility score than men, 0.76 and 0.85 respectively (p = 0.0217).
The utility score ranged from 0.92 in the youngest age group
(age 20–45) to 0.78 to the oldest age group (age 61–65) (p =
0.02). CONCLUSION: Type 1 diabetes patients reported a
higher HRQL than Type 2 diabetes patients. Women had signif-
icantly lower EQ-5D score than men.
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OBJECTIVE: To test the hypothesis that improved nerve func-
tion using the anti-epileptic/migraine drug topiramate would
translate to better quality of life (QOL). METHODS: Twenty
patients with diabetic peripheral neuropathy were consented and
entered into a study on topiramate. The dosage for each patient
was titrated over a six-week period from 25mg per day to 50
mg twice a day. The patients remained on 100mg a day for 12
weeks and then were tapered off the medication over an addi-
tional 4-week period. Each patient received quantitative sensory
testing, electromyography, skin blood ﬂow, skin biopsies, and
neurological examinations before and after treatment with top-
